GLP-1 drugs and alcohol cravings: what the trial evidence shows

Key takeaways

• A phase 2 randomized controlled trial published in JAMA Psychiatry in 2025 reported that low-dose semaglutide (0.25 mg per week titrating up to 1.0 mg) reduced weekly alcohol craving, drinks per drinking day, and laboratory self-administration in 48 adults with alcohol use disorder over 9 weeks .
• A 26-week randomized trial of exenatide 2 mg once weekly (n=127, treatment-seeking adults) did not significantly reduce heavy drinking days in the overall sample, but did reduce alcohol-cue reactivity in the ventral striatum on fMRI, and reduced heavy drinking days in a prespecified subgroup with BMI greater than 30 .
• A 2024 real-world cohort study (n=83,825 patients with obesity and 598,803 with type 2 diabetes) found that semaglutide use was associated with roughly 50 to 56 percent lower 12-month risk of both new and recurrent alcohol use disorder versus other anti-obesity medications .
• A 2025 systematic review and meta-analysis (11 studies, 3 randomized trials and 8 observational, 263,616 patients) reported lower alcohol-related events (hazard ratio 0.56) and lower liver-related outcomes (incidence rate ratio 0.65) with GLP-1 receptor agonist exposure. The pooled effect on total alcohol intake was not statistically significant (standardized mean difference -0.17) .
• No GLP-1 receptor agonist is FDA-approved for alcohol use disorder. Approved indications for semaglutide (Ozempic) are type 2 diabetes glycemic control, cardiovascular risk reduction, and chronic kidney disease outcomes; tirzepatide (Mounjaro) is approved for type 2 diabetes .
• For research and educational purposes only. Not medical advice.

Why this question is suddenly everywhere

Anyone reading r/Semaglutide, r/Mounjaro, r/Zepbound, or r/Ozempic in the last two years has seen the same anecdote on repeat: someone starts a GLP-1 receptor agonist for weight or blood sugar, and a few weeks in notices they just do not want to drink anymore. Sometimes the desire fades. Sometimes one drink is enough where five used to be.

Anecdote is not evidence, but in this case the anecdote outran the trials and pulled researchers in. A 2023 mixed-methods Reddit analysis classified roughly 1,580 alcohol-related GLP-1 posts and reported that about 72 percent described reduced cravings, reduced usage, or a worsened experience of drinking . That early pattern is what catalyzed the formal randomized trials we now have.

GLP-1 stands for glucagon-like peptide-1, a gut-derived hormone that signals satiety and slows gastric emptying. The receptor agonists in this class (semaglutide, tirzepatide, exenatide, liraglutide, dulaglutide) were developed for diabetes and obesity. The alcohol question is an off-label hypothesis now being tested in adults with alcohol use disorder.

What the 2025 semaglutide trial actually showed

The Hendershot 2025 trial published in JAMA Psychiatry is the first randomized controlled trial of semaglutide in adults with alcohol use disorder. It was a phase 2, double-blind, parallel-arm study run at a single US academic medical center, with 48 non-treatment-seeking adults randomized over a 9-week outpatient course .

• Dose schedule: semaglutide 0.25 mg per week for 4 weeks, 0.5 mg per week for 4 weeks, then 1.0 mg for 1 week. This is the same titration ramp used at the start of standard diabetes dosing, and is much lower than typical obesity-treatment maintenance doses.
• Population: 48 adults with alcohol use disorder, average age 39.9 years, 71 percent women. Participants were not seeking treatment, which matters: this is a pharmacology signal, not a behavioral-therapy effect.
• Primary outcomes: drinks per drinking day, total alcohol craving, and a posttreatment laboratory alcohol self-administration session.
• Results: relative to placebo, semaglutide reduced laboratory self-administration drinking, significantly reduced weekly alcohol craving, and reduced drinks per drinking day. Effect sizes on several measures were described as medium to large.
• Smoking signal: in a participant subgroup who smoked cigarettes at baseline, semaglutide produced a greater reduction in cigarettes per day than placebo.

The trial is small, single-site, short, and used semaglutide doses well below typical obesity maintenance levels. That is a feature, not a bug, for a first-in-class signal-finding trial. The honest read is that the signal is real and consistent across multiple measures, but the magnitude, durability, dose-response curve, and behavior in treatment-seeking populations are still open questions.

The 2022 exenatide trial: a null primary, a positive brain signal

The Klausen 2022 trial in JCI Insight is the most-cited earlier GLP-1 randomized trial in alcohol use disorder. It was larger and longer than the Hendershot study, and the result is more nuanced .

• Design: double-blind, placebo-controlled randomized trial, 26 weeks of treatment, in addition to standard cognitive-behavioral therapy for alcohol use disorder.
• Intervention: exenatide 2 mg subcutaneously once weekly, the licensed Bydureon dosing schedule used in type 2 diabetes.
• Population: 127 treatment-seeking adults with alcohol use disorder.
• Primary endpoint: heavy drinking days. Result in the overall sample: not statistically significant versus placebo.
• Imaging endpoint: cue-induced fMRI activity in the ventral striatum and septal area, brain regions central to drug reward, was significantly lower after exenatide than after placebo. Dopamine transporter availability was also lower in the exenatide arm.
• Prespecified subgroup: in participants with BMI greater than 30, exenatide significantly reduced heavy drinking days and total alcohol intake.

How to read a trial that missed its primary endpoint but moved a brain-imaging endpoint and helped a subgroup: cautiously, and with attention to the mechanism question. The fMRI finding is consistent with the preclinical work showing GLP-1 receptor activation dampens mesolimbic dopamine response to alcohol. The BMI greater-than-30 subgroup effect supports the hypothesis, embedded in much of the 2024 to 2025 literature, that the alcohol-suppressing signal may be strongest in people whose obesity and addiction biology overlap.

Real-world cohort and meta-analysis evidence

Outside randomized trials, two large electronic health record analyses and several systematic reviews now cover the question. The largest is Wang et al. 2024 in Nature Communications, a retrospective cohort study of US electronic health records covering 83,825 patients with obesity and 598,803 patients with type 2 diabetes, comparing semaglutide to other anti-obesity or anti-diabetic medications across a 12-month follow-up .

• Semaglutide exposure was associated with roughly 50 to 56 percent lower 12-month risk of new alcohol use disorder diagnoses and of recurrence in adults with prior AUD history, versus controls.
• The association held across subgroups by sex, age, and race, and in patients with and without type 2 diabetes.
• This is observational data, vulnerable to indication bias and unmeasured confounding. Patients prescribed semaglutide differ from those who are not, in ways the EHR cannot fully adjust for. The signal is large and directionally consistent with the RCTs, but real-world cohort studies cannot, on their own, establish causation.

A 2023 self-report survey in Scientific Reports of 153 current drinkers with BMI at or above 30 compared semaglutide or tirzepatide users to unmedicated controls and reported significantly lower alcohol intake, fewer drinks per drinking episode, lower binge-drinking odds, and lower Alcohol Use Disorders Identification Test (AUDIT) scores in the medication groups . Self-report has obvious limits, but the direction is consistent with the EHR data.

A 2025 systematic review and meta-analysis (Moraes et al., Drug and Alcohol Dependence) pooled 11 studies including 3 randomized trials and 8 observational analyses, covering 263,616 patients (124,884 on GLP-1 receptor agonists and 138,732 controls). The pooled analysis found lower rates of alcohol-related events (hazard ratio 0.56, 95 percent CI 0.48 to 0.65) and lower liver-related outcomes (incidence rate ratio 0.65, 95 percent CI 0.50 to 0.85). The pooled effect on total alcohol intake was not statistically significant (standardized mean difference -0.17, 95 percent CI -0.39 to 0.04) .

How GLP-1 drugs may blunt alcohol cravings in the brain

GLP-1 receptors are expressed not only in the pancreas and gastrointestinal tract but also in central nervous system regions that regulate reward and motivation, including the ventral tegmental area, nucleus accumbens shell, and lateral dorsal tegmental nucleus. These are the same circuits that alcohol, palatable food, nicotine, and other reinforcing stimuli act on.

A 2018 Neuropharmacology review by Jerlhag summarized the preclinical evidence: GLP-1 receptor activation, either by endogenous GLP-1 or by drug analogues, attenuates the ability of alcohol to activate the mesolimbic dopamine system. In rodent models, GLP-1 receptor agonists reduce alcohol-induced dopamine release in the nucleus accumbens, reduce alcohol-induced conditioned place preference, and reduce voluntary alcohol intake in high-drinking rats. The effect appears to require GLP-1 receptors in specific brain regions, not the pancreas .

The Klausen trial provided a direct human translation of this finding: exenatide reduced fMRI cue reactivity in the ventral striatum, the same circuit that lights up when alcohol-dependent people see an alcohol cue. So even when the heavy-drinking-days endpoint did not move, the neural signature of cue-induced reward was muted. This is consistent with the broader pattern in the literature, which is that GLP-1 receptor agonists seem to reduce the wanting of alcohol more reliably than the absolute amount consumed in unselected populations.

What the evidence does not yet show

• No FDA-approved indication. As of the 2025 labels, semaglutide is approved for type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease outcomes; tirzepatide is approved for type 2 diabetes; the obesity-indicated branded products (Wegovy, Zepbound) are approved for chronic weight management. None list alcohol use disorder, alcohol dependence, or any substance use disorder as an indication .
• No established dose for alcohol-related outcomes. The Hendershot trial used a low semaglutide dose. The Klausen trial used a standard diabetes dose of exenatide. Whether higher obesity-range semaglutide doses produce a larger alcohol effect or a smaller one is not yet established.
• No durability data. The longest published randomized trial is 26 weeks. Whether the effect persists at 12 or 24 months, and what happens when the drug is stopped, is unstudied in this indication.
• Limited data in alcohol-only populations. Most of the human evidence is in adults with overlapping obesity, type 2 diabetes, or both. The signal in lean adults with alcohol use disorder alone is much thinner.
• Risk-benefit unsettled for AUD-only use. Gastrointestinal side effects, pancreatitis signals, gastroparesis case reports, and the existing thyroid C-cell tumor warning on the semaglutide and tirzepatide labels all apply if these drugs are used for alcohol-related reasons. The trade-off math is different from the diabetes or obesity case.
• Comparative effectiveness is unknown. Naltrexone, acamprosate, and disulfiram are FDA-approved for alcohol use disorder. No head-to-head trial of a GLP-1 receptor agonist against any of them has reported results yet.

Frequently asked questions

Does semaglutide reduce alcohol cravings? The 2025 Hendershot phase 2 RCT in JAMA Psychiatry reported a statistically significant reduction in weekly alcohol craving versus placebo in adults with alcohol use disorder over 9 weeks of low-dose treatment. This is one trial; replication in larger studies is in progress .

Is Ozempic approved for alcohol use disorder? No. The 2025 Ozempic prescribing information lists type 2 diabetes glycemic control, major adverse cardiovascular event risk reduction, and kidney disease outcomes as the FDA-approved indications. Alcohol use disorder is not on the label .

How might GLP-1 drugs reduce drinking? GLP-1 receptors in the reward circuitry modulate dopamine response to alcohol. Preclinical work shows GLP-1 receptor agonists reduce alcohol-induced dopamine release and voluntary alcohol intake in animal models. The Klausen 2022 trial showed exenatide reduced human fMRI cue reactivity in the ventral striatum .

Does tirzepatide also reduce alcohol intake? The published human data is observational. The Quddos 2023 self-report survey reported significantly lower alcohol intake, drinks per episode, binge odds, and AUDIT scores in semaglutide or tirzepatide users versus controls. No dedicated randomized trial of tirzepatide for alcohol use disorder has reported results yet .

Is the effect stronger in people with obesity? The Klausen exenatide trial reported a significant reduction in heavy drinking days specifically in the prespecified BMI greater than 30 subgroup, despite a null primary effect in the overall sample. The Quddos survey was restricted to adults with BMI at or above 30. Whether the signal generalizes to lean adults with alcohol use disorder is one of the open questions in the literature .

Are larger trials coming? Yes. Multiple phase 2 and phase 3 GLP-1 trials with alcohol-related endpoints are registered on ClinicalTrials.gov. The Hendershot 2025 trial was registered as NCT05520775 .

Editorial summary

The GLP-1 and alcohol question used to be a Reddit anecdote. As of 2026 it is a published phase 2 RCT signal, a 26-week exenatide trial with mechanistic support, a real-world cohort consistent with both, and a systematic review aligned on direction. The next 24 months of larger trials will determine whether GLP-1 receptor agonists earn a place in the alcohol use disorder toolkit, or stay an interesting off-label observation.

What is not yet settled: the dose-response curve, the durability of effect, the comparative effectiveness versus existing alcohol-use-disorder medications, the magnitude in lean adults without obesity, and the long-run risk-benefit profile when the indication is alcohol-related rather than metabolic.